Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Teva Pharma Industries Ltd ADR stake
total: 652
Viking Global Investors TEVA trades
- Total transactions:
- 14
- New positions:
- 3
- Sold out:
- 3
- Added:
- 4
- Reduced:
- 4
- Held since:
- 2024 Q3
- Held for:
- 5 quarters
- Latest activity:
- 2025 Q4
According to 2026 Q1 report, Ole Andreas Halvorsen doesn't hold any Teva Pharma Industries Ltd ADR (TEVA) shares. To date, the estimated cost basis is nearly $17.11 for "buy" trades and estimated average "sell" price is $20.35. Viking Global Investors first purchased TEVA in 2015 Q1, initially acquiring 228,600 shares. Ole Andreas Halvorsen later completely sold out the position and invested in Teva Pharma Industries Ltd ADR again in 2024 Q3. Since the initial investment in Teva Pharma Industries Ltd ADR (TEVA), Viking Global Investors has made 13 more transactions.
When did Ole Andreas Halvorsen sell Teva Pharma Industries Ltd ADR (TEVA)?
Ole Andreas Halvorsen sold off the entire Teva Pharma Industries Ltd ADR (TEVA) position in 2025 Q4.
When did Ole Andreas Halvorsen buy Teva Pharma Industries Ltd ADR (TEVA)?
Ole Andreas Halvorsen first invested in Teva Pharma Industries Ltd ADR (TEVA) in 2015 Q1 at the reported quarter-end price of $62.30 per share.
What's the cost basis of Viking Global Investors's TEVA stake?
The estimated cost basis for Teva Pharma Industries Ltd ADR (TEVA) stake is around $17.11 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $17.11
- Weighted AVG sell price:
- $20.35
Ole Andreas Halvorsen's historical trades in Teva Pharma Industries Ltd ADR
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
0.00%
|
0
|
$20.20
|
|
-100% (-2,532,119)
|
-0.13%
|
|
2025 Q3
|
0.13%
|
2,532,119
|
$20.20
|
$51,148,804
|
-78.32% (-9,149,214)
|
-0.53%
|
|
2025 Q2
|
0.57%
|
11,681,333
|
$16.76
|
$195,779,141
|
+15.37% (+1,555,855)
|
+0.08%
|
|
2025 Q1
|
0.49%
|
10,125,478
|
$15.37
|
$155,628,597
|
+55.69% (+3,621,993)
|
+0.18%
|
|
2024 Q4
|
0.46%
|
6,503,485
|
$22.04
|
$143,336,809
|
-14.06% (-1,064,048)
|
-0.09%
|
|
2024 Q3
|
0.50%
|
7,567,533
|
$18.02
|
$136,366,945
|
new
|
+0.5%
|
|
2016 Q4
|
0.00%
|
$46.01
|
-100% (-19,684,219)
|
|||
|
2016 Q3
|
3.91%
|
$46.01
|
-29.03% (-8,052,436)
|
|||
|
2016 Q2
|
5.92%
|
$50.23
|
-15.88% (-5,234,967)
|
|||
|
2016 Q1
|
7.77%
|
$53.51
|
+31.66% (+7,927,847)
|
|||
|
2015 Q4
|
6.20%
|
$65.64
|
+182.26% (+16,171,125)
|
|||
|
2015 Q3
|
1.92%
|
$56.46
|
new
|
|||
|
2015 Q2
|
0.00%
|
$62.30
|
-100% (-228,600)
|
|||
|
2015 Q1
|
0.06%
|
$62.30
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.